Table 3.
Progression-free and overall survival, overall response rate and CNS metastases among patients treated with EGFRm+ mNSCLC
| Outcome | Total (N = 162) |
|---|---|
| Follow-up time, months, median (IQR) | 15.6 (13.7–17.3) |
| Alive at time of data abstraction, n (%) | 146 (90.1) |
| CNS metastases | |
| Number of patients without CNS involvement at the time of 1L treatment initiation, n (%) | 127 (78.4) |
| Developed CNS metastases after 1L treatment initiationa | 4 (3.1) |
| Overall Tumour Response rate (ORR) at 1L treatmentb, % (95% CI) | 75.9 (67.6–84.3) |
| First-line progression-free survival | |
| Eventc, n (%) | 70 (43.2) |
| Censored, n (%) | 92 (56.8) |
| 12-month PFS, % (95% CI) | 63.8 (55.8–70.8) |
| 18-month PFS, % (95% CI) | 53.1 (44.2–61.3) |
| Median PFS, months (95% CI) | NR (14.7–NR) |
| Overall survival from 1L treatment | |
| Death, n (%) | 10 (6.2) |
| Alive (censored), n (%) | 152 (93.8) |
| 12-month survival, % (95% CI) | 94.8 (89.9–97.4) |
| 18-month survival, % (95% CI) | 92.0 (84.8–95.8) |
| Median survival, months (95% CI) | NR |
CI confidence interval, CNS central nervous system, CR complete response, IQR interquartile range, N total number of subjects, n number of subjects per category, NR not reached, NSCLC non-small cell lung cancer, ORR overall tumour response rate, PR partial response
aThe duration between commencement of first-line treatment and CNS development for these patients range from 176.0 to 513.0 days
b95% CIs adjusted for clustering. At least one PR or CR assessment determination
cAn event is discontinuation of treatment due to disease progression, death, or commencement of the next line of therapy